Pulmonary rehabilitation for interstitial lung disease

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 1, 2021, Pages

  Dowman, Leona ^a,b,c   Hill, Catherine J ^b,f   May, Anthony ^c,e   Holland, Anne E ^b,c,d  

^a AUSTIN HEALTH   (Australia)

^b Institute for Breathing and Sleep   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d ALFRED HEALTH   (Australia)

^e DEAKIN UNIVERSITY   (Australia)

^f AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOSIS; DISEASE SEVERITY; DYSPNEA; EXERCISE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG SARCOIDOSIS; PATIENT PARTICIPATION; PATIENT SAFETY; PNEUMOCONIOSIS; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIX MINUTE WALK TEST; SURVIVAL RATE; SYSTEMATIC REVIEW; THERAPY EFFECT; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 85102729430     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006322.pub4     Document Type: Review

References (91)

1. Baradzina H. Short and long-term effects of pulmonary rehabilitation program in sarcoidosis. European Respiratory Journal 2013;42(Suppl 57):789S. x-wiley/crsRef/3185315
2. Baradzina HL, Ponachevnaya NV. Pulmonary rehabilitation programme in sarcoidosis. European Respiratory Journal 2005;26(Suppl 49):333S. x-wiley/crsRef/3185316
3. Dale M, McKeough Z, Munoz P, Corte P, Bye P, Alison JE. Exercise training improves exercise capacity and quality of life in people with dust-related pleural and interstitial respiratory diseases: a randomised controlled trial. European Respiratory Journal 2011;38(Suppl 55):261s. x-wiley/crsRef/15989044
4. Dale M, McKeough ZJ, Munoz PA, Corte P, Bye PT, Alison J. Exercise training for asbestos-related and other dust-related respiratory diseases: a randomised controlled trial. BMC Pulmonary Medicine 2014;14(180):1-9. x-wiley/crsRef/15989045 [DOI: 10.1186/1471-2466-14-180]
5. De Las Heras JC, Hilberg O, Lokke A, Bendstrup E. Tele-rehabilitation program in idiopathic pulmonary fibrosis. European Respiratory Journal 2019;54(Suppl 63):PA2232. x-wiley/crsRef/15989047 [DOI: 10.1183/13993003.congress-2019.PA2232]
6. Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, et al. Effect of disease aetiology on response to exercise training in patients with interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 2015;181:A2460. x-wiley/crsRef/15989049
7. Dowman L, McDonald CF, Hill C, Lee A, Barker K, Boote C, et al. Effect of disease aetiology on response to exercise training in patients with interstitial lung disease. Respirology 2015;20(Suppl 2):13-61. x-wiley/crsRef/15989050
8. Dowman LM, McDonald CF, Hill CJ, Lee AL, Barker K, Boote C, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax 2017;72:610-9. x-wiley/crsRef/15989051
9. Gaunaurd IA, Gomez-Marin OW, Ramos CF, Sol CM, Cohem MI, Cahalin LP, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respiratory Care 2014;59(12):1872-9. x-wiley/crsRef/16238366
10. Gomez O, Gaunaurd IA, Cohen M, Cardenas D, Cahalin L, Ramos C. Health related quality of life in IPF patients on a pulmonary rehabilitation program. American Journal of Respiratory and Critical Care Medicine 2013;187:A1814. x-wiley/crsRef/16238367
11. He H, Hao J, Le S, Qian J, Li L, Li C, et al. The effect of cardiopulmonary rehabilitation training on lung function in patients with moderate IPF. Journal of Clinical Pulmonary Medicine 2016;21(3):492-4. x-wiley/crsRef/15989056
12. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short-term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63:549-5. x-wiley/crsRef/3185318
13. Cohen MI, Cahalin LP, Gaunaurd IA, Ramos C, Cardonas D, Gomez-Marin O, et al. Respiratory muscle performance before and after pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Cardiopulmonary Physical Therapy Journal 2013;24(4):44. x-wiley/crsRef/3185320
14. Gaunaurd I, Eustis N, Cohen M, Tamos C, Sol C, Cardenas D, et al. Rehabilitation of patients with idiopathic pulmonary fibrosis: changes in quality of life, functional mobility, and oxygen metabolism. Cardiopulmonary Physical Therapy Journal 2011;22(4):30-1. x-wiley/crsRef/3185321
15. Gaunaurd IA, Gomez-Marin O, Ramos D, Cardenas D, Cahalin L, Cohen M, et al. Effects of a pulmonary rehabilitation on exercise capacity and functional mobility for patients with IPF. American Journal of Respiratory and Critical Care Medicine 2013;187:A1800. x-wiley/crsRef/3185322
16. Jackson R, Ramos C, Cardenas D, Sol C, Cohen M, Gaunaurd I, et al. Effects of aerobic and strength training on symptoms and exercise capacity of IPF patients. European Respiratory Journal 2012;40(Suppl 56):672s. x-wiley/crsRef/3185324
17. Jackson RM, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung 2014;192(3):367-76. x-wiley/crsRef/3185325
18. Jackson RM, Ramos CF, Cardenas D, Gaunaurd I, Eustis N, Cohen M, et al. Effects of aerobic and strength training on symptoms and exercise capacity of IPF patients. American Journal of Respiratory and Critical Care Medicine 2012;185:A2398. x-wiley/crsRef/3185326
19. Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Frankenberger M, Neurohr C, et al. Short-term effects of comprehensive pulmonary rehabilitation and its maintenance in patients with idiopathic pulmonary fibrosis: a randomized controlled trial. Journal of Clinical Medicine 2020;9(5):1567. x-wiley/crsRef/15989058 [DOI: doi.org/10.3390/jcm9051567]
20. Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Neurohr C, Prasse A, et al. Effects of a 3-week pulmonary rehabilitation program in patients with idiopathic pulmonary fibrosis – a randomized, controlled trial. European Respiratory Journal 2016;48:OA3050. x-wiley/crsRef/15989059
21. Ku V, Janmeja AK, Aggarwal D, Sood P. Pulmonary rehabilitation in patients with interstitial lung diseases in an outpatient setting: a randomised controlled trial. Indian Journal of Chest Diseases and Allied Sciences 2017;59:75-80. x-wiley/crsRef/15989061
22. Lanza M, Meoli I, Cauteruccio R, Stefanelli F, Di Giorgio A, Annunziata A, et al. Short and long-term effects of pulmonary rehabilitation in idiopathic pulmonary fibrosis: the evidence of benefits of exercise training. European Respiratory Journal 2019;54(Suppl 63):PA678. x-wiley/crsRef/15989063
23. Mejia RA, Sansores RH, Perez-Padilla R, Mahler DA. Effects of exercise training on 'quality of life' in patients with interstitial lung diseases. European Respiratory Journal 2000;16(Suppl 31):330s. x-wiley/crsRef/3185328
24. Menon B, Vijayan VK, Bansal V, Prajapat B. Effect of pulmonary rehabilitation on gas exchange, muscle cross section area and functional parameters in interstitial lung disease. European Respiratory Journal 2011;38:878s. x-wiley/crsRef/3185330
25. Prajapat B, Menon B, Bansal V, Vijayan V. Effect of mid thigh cross sectional area on CT as a marker of muscle mass in interstitial lung diseases after pulmonary rehabilitation. In: 16th Congress of the Asian Pacific Society of Respirology; 2011 Nov 3-6; Shanghai (PRC). 2011. x-wiley/crsRef/3185331
26. Naz I, Ozalevli S, Ozkan S, Sahin H. Effectiveness of a structural exercise program on six minutes walk distance in patients with stage 3 and 4 sarcoidosis. A randomized control trial. European Respiratory Journal 2016;48:PA690. x-wiley/crsRef/15989065
27. Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a structured exercise program for improving functional capacity and quality of life in patients with stage 3 and 4 sarcoidosis. A randomized controlled trial. Journal of Cardiopulmonary Rehabilitation and Prevention 2018;38:124-30. x-wiley/crsRef/15989066
28. Nishiyama O, Kondoh Y, Kimura T, Kato K, Kataoka A, Ogawa T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008;13:394-9. x-wiley/crsRef/3185333
29. Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Ogawa T, Watanabe F, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis. In: American Thoracic Society 100th International Conference; 2008 May 21-26; Orlando (FL). 2004:D96 Poster 110. x-wiley/crsRef/3185334
30. Barbier V, Hornikx M, Coosemans I, Muylaert I, Wuyts W, Janssens W, et al. Survival rates after a pulmonary rehabilitation program in patients with interstitial lung disease. European Respiratory Journal 2014;44(Suppl 58):P4282. x-wiley/crsRef/15989068
31. Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respiratory Research 2018;19(182):1-10. x-wiley/crsRef/15989069
32. Perez Bogerd S, Wuyts W, Barbier V, Langer D, Burtin C, Van Remoortel H, et al. Preliminary results of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial B32220095560. European Respiratory Journal 2011;38:259s. x-wiley/crsRef/15989070
33. Shen L, Li QH, Weng D. The preliminary evaluation of the effectiveness and safety of pulmonary fibrosis rehabilitation exercise. American Journal of Respiratory and Critical Care Medicine 2016;193:A5010. x-wiley/crsRef/15989072
34. Kramer M, Vainshelboim B, Oliveira J, Yohoshua L, Wais I, Rusanov V, et al. Pulmonary rehabilitation improves exercise capacity and function in patients with idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 2013;187:A1832. x-wiley/crsRef/15989074
35. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Exercise training based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration 2014;88(5):378-88. x-wiley/crsRef/15989075
36. Vainshelboim B, Oliveira J, Fox BD, Soreck Y, Fruchter O, Kramer MR. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung 2015;193(3):345-54. x-wiley/crsRef/15989076
37. Vainshelboim B, Oliveira L, Yohoshua L, Weis I, Fox B, Kramer M. The effect of pulmonary rehabilitation on exercise tolerance, pulmonary function, dyspnea and quality of life in patients with idiopathic pulmonary fibrosis. European Respiratory Journal 2013;187:A1832. x-wiley/crsRef/15989077
38. Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: a randomized controlled trial. Respiratory Medicine and Research 2020;77:1-7. x-wiley/crsRef/15989079
39. Behnke M, Schwertfeger I, Zimmerman I, Kirsten D, Joerres RA, Magnussen H. Home-based exercise training in patients with interstitial lung disease. European Respiratory Journal 2003;22(Suppl 45):1081. x-wiley/crsRef/3185341
40. Wewel AR, Behnke M, Schwertfeger I, Eberhardt F, Kroidl RF, Jorres RA, et al. Home-based walking training in patients with interstitial lung diseases. European Respiratory Journal 2005;26(Suppl 49):528S. x-wiley/crsRef/3185342
41. Xiao K, Liu JH, Ding XP, Cui FT, Wang HB, Wang MM, et al. Comprehensive rehabilitation of individualized exercise program for coal workers pneumoconiosis in Huaibei Coal Mine Group. Chinese Journal of |Industrial Hygiene and Occupational Diseases 2019;37(5):357-61. x-wiley/crsRef/15989081
42. Arizono S, Taniguchi H, Sakamoto K, Kondoh Y, Kimura T, Kataoka K, et al. Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. Respiratory Care 2014;59(7):1108-15. x-wiley/crsRef/15989083
43. Cockcroft AE, Saunders MJ, Berry G. Randomised controlled trial of rehabilitation in chronic respiratory disability. Thorax 1981;36:200-3. x-wiley/crsRef/3185346
44. Cockcroft AE, Berry G, Brown EB, Exall C. Psychological changes during a controlled trial of rehabilitation in chronic respiratory disability. Thorax 1982;37:413-6. x-wiley/crsRef/3185348
45. Daltroy LH, Robb-Nicholson C, Iverson MD, Wright EA, Liang MH. Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease. British Journal of Rheumatology 1995;34:1064-9. x-wiley/crsRef/3185350
46. Greening N, Williams JE, Hussain SF, Harvey-Dunstan TC, Bankart J, Chaplin EJ, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ 2014;349(g4315):1-12. x-wiley/crsRef/15989085
47. Igarashi A, Iwanami Y, Sugino K, Gocho K, Homma S, Ebihara S. Using 6-min walk distance expressed as a percentage of reference to evaluate the effect of pulmonary rehabilitation in elderly patients with interstitial lung disease. Journal of Cardiopulmonary Rehabilitation and Prevention 2018;38(5):342-7. x-wiley/crsRef/15989087
48. Jastrzebski D, Gumola A, Gawlik R, Kozielski J. Dyspnoea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. Journal of Physiology and Pharmacology 2006;57(Suppl 4):139-48. x-wiley/crsRef/3185352
49. Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, et al. Efficacy of a tailored rehabilitation program for systemic sclerosis. Clinical and Experimental Rheumatology 2009;27(Suppl 54):S44-50. x-wiley/crsRef/16238369
50. Naji NA, Connor MC, Donnelly SC, McDonnell TJ. Effectiveness of pulmonary rehabilitation in restrictive lung disease. Journal of Cardiopulmonary Rehabilitation 2006;26:237-43. x-wiley/crsRef/3185356
51. Nakazawa A, Hagiwara E, Yamaguchi O, Ogata R, Shinohara T, Matsumoto Y, et al. Efficacy of pulmonary rehabilitation in patients with interstitial lung disease. European Respiratory Journal 2012;40:1896. x-wiley/crsRef/3185358
52. Nikoletou D, Lech C, McNaughton I, Aul R, Chis-Ster I, Jones PW. High intensity interval versus moderate intensity continuous training in a pulmonary rehabilitation programme for patients with interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 2016;193:A4520. x-wiley/crsRef/15989089
53. Oh E. The effects of home-based pulmonary rehabilitation in patients with chronic lung disease. International Journal of Nursing Studies 2003;40:873-9. x-wiley/crsRef/3185360
54. Ong KC, Wong WP, Jailani AR, Sew S, Ong YY. Effects of a pulmonary rehabilitation programme on physiologic and psychosocial outcomes in patients with chronic respiratory disorders. Annals of the Academy of Medicine, Singapore 2001;30:15-21. x-wiley/crsRef/3185362
55. Sciriha A, Lungaro-Mifsud S, Fsadni P, Scerri J, Montefort S. Pulmonary rehabilitation in patients with interstitial lung disease: the effects of a 12-week programme. Respiratory Medicine 2019;146:49-56. x-wiley/crsRef/15989091
56. Senstrom CH, Arge B, Sundbom A. Dynamic training vs relaxation training as home exercise for patients with inflammatory rheumatic diseases. Scandinavian Journal of Rheumatology 1996;25:28-33. x-wiley/crsRef/3185364
57. Senstrom CH, Arge B, Sundbom A. Home exercise and compliance in inflammatory rheumatic diseases – a prospective clinical trial. Journal of Rheumatology 1997;24:470-6. x-wiley/crsRef/3185366
58. Stessel M, Wapenaar M, Huremovic J, Bendstrup E, Molina M, Wijsenbeek M. The efficacy of a walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). A pilot study. European Respiratory Journal 2015;46:PA2038. x-wiley/crsRef/15989093
59. Tryfon SM, Mavrofridis E, Ilonidis G, Patakas D. Cardiopulmonary effects of exercise, before and after oxygen delivery, in patients with usual interstitial pneumonia. European Respiratory Journal 2003;22(Suppl 45):P639. x-wiley/crsRef/3185368
60. Yuen HK, Lowman JD, Oster RA, de Andrade JA. Home-based pulmonary rehabilitation for patients with idiopathic pulmonary fibrosis: a pilot study. Journal of Cardiopulmonary Rehabilitation and Prevention 2019;39(4):281-4. x-wiley/crsRef/15989095
61. El-Komy H, Awad M, Mansour W, Elsayed EI. Impact of pulmonary rehabilitation on patients with interstitial lung diseases: an Egyptian experience. Egyptian Journal of Bronchology 2019;13:219-25. x-wiley/crsRef/15989097
62. Kondoh Y, Taniguchi H, Kataoka K, Arizono S, Ogawa T, Watanabe F, et al. Long-term effect of pulmonary rehabilitation under nintedanib treatment in idiopathic pulmonary fibrosis: methodology of the fitness study. American Journal of Respiratory and Critical Care Medicine 2017;195:A4280. x-wiley/crsRef/15989099
63. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. American Review of Respiratory Disease 1991;143(2):219-25.
64. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 2011;183(6):788-852.
65. Bolton CE, Bevan-Smith EF, Blakey JD, Crowe P, Elkin SL, Garrod R, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. Thorax 2013;68:ii1-ii30.
66. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl 5):v1-v58.
67. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health-related quality of life in patients with interstitial lung disease. Chest 1999;116(5):1175-82.
68. Flaherty KR, White ES, Gay SE, Martinez FJ, Lynch JP. Timing of lung transplantation for patients with fibrotic lung diseases. Seminars in Respiratory Critical Care Medicine 2001;22:517-32.
69. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SL, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. New England Journal of Medicine 2019;18:1718-27. [DOI: 10.1056/NEJMoa1908681]
70. Graney BA, Lee JS. Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Related Outcome Measures 2018;9:321-8. [DOI: 10.2147/PROM.S144425]
71. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996;109(6):1566-76.
72. Harris-Eze AO, Sridhar G, Clemens RE, Zintel TA, Gallagher CG, Marciniuk DD. Role of hypoxemia and pulmonary mechanics in exercise limitation in interstitial lung disease. American Journal of Respiratory and Critical Care Medicine 1996;154(4 Pt 1):994-1001.
73. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
74. Holland AE, Wadell K, Spruit MA. How to adapt the pulmonary rehabilitation programme to patients with chronic respiratory disease other than COPD. European Respiratory Review 2013;22(130):577-86.
75. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. European Respiratory Journal 2014;44(6):1428-46. [DOI: 10.1183/09031936.00150314]
76. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials 1989;10(4):407-15.
77. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine 2013;189(3):250-5. [DOI: 10.1164/rccm.201310-1863PP]
78. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. New England Journal of Medicine 2014;370(22):2083-92.
79. Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, et al. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. Respiratory Research 2020;21(1):36. [DOI: 10.1186/s12931-020-1298-1]
80. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No: CD003793. [DOI: 10.1002/14651858.CD003793.pub2]
81. Lama VN, Martinez FJ. Resting and exercise physiology in interstitial lung diseases. Clinical Chest Medicine 2004;25:435-53.
82. Markovitz GH, Cooper CB. Exercise and interstitial lung disease. Current Opinion in Pulmonary Medicine 1998;4(5):272-80.
83. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No: CD003793. [DOI: 10.1002/14651858.CD003793.pub3]
84. Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine 2019;153:44-51. [DOI: doi.org/10.1016/j.rmed.2019.04.016]
85. Puhan MA, Chandra D, Mosenifar Z, Reis A, Make B, Hansel NN, et al. The minimal important difference of exercise tests in severe COPD. European Respiratory Journal 2011;37(4):784-90.
86. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. Journal of Clinical Epidemiology 1996;49:1215-9.
87. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New England Journal of Medicine 2014;370(22):2071-82.
88. Spruit MA, Singh SJ, Garvey C, Zuwallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine 2013;188(8):e13-e62.
89. Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respiratory Medicine 2010;104:296-304.
90. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No: CD006322. [DOI: 10.1002/14651858.CD006322.pub3]
91. Holland AE, Hill C. Physical training for interstitial lung disease. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No: CD006322. [DOI: 10.1002/14651858.CD006322.pub2]